Radiopharmaceutical Theranostics Market
Report ID: SQMIG35I2494
Report ID: SQMIG35I2494
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35I2494 |
Region:
Global |
Published Date: January, 2026
Pages:
187
|Tables:
117
|Figures:
72
Global Radiopharmaceutical Theranostics Market size was valued at USD 2.3 billion in 2024 and is poised to grow from USD 2.57 billion in 2025 to USD 6.23 billion by 2033, growing at a CAGR of 11.7% during the forecast period (2026-2033).
Due to the growing incidence of cancers and neurological diseases, the development and application of targeted therapies has gained strong interest in radiopharmaceutical theranostics, which combines the diagnostic and therapeutic actions in one procedure, that can improve patient care by increasing efficiency and outcomes.
Increasing recognition of precision medicine, more funding in nuclear medicine, and improvements in imaging technology are enabling greater acceptance of radiopharmaceutical theranostics, and more hospitals and research institutes are implementing these solutions as they can be used for providing early detection of disease and in real-time for assessing treatment. Radiopharmaceutical theranostics market share in the future looks bright with support from regulators and partnerships with pharmaceutical and biotechnology companies that will support innovation and accelerate global market access.
Significant costs for development, regulatory requirements, isotope availability and safety concerns associated with radioactive materials may hinder radiopharmaceutical theranostics market growth for some time. Also, many countries will not be able to implement radiopharmaceutical theranostics for the long-term because they do not have the skilled workforce or infrastructure.
How Are Theranostic Radiopharmaceuticals Used More Widely in Cancer Care?
Theranostic radiopharmaceuticals are taking hold in oncology, allowing physicians to diagnose cancer through the same molecular entity that they can then use to treat the patient. This allows physicians to localize the tumor precisely and then provide radiation therapy directly to the tumor without harming much of the adjacent healthy tissues. Patients can expect to receive more rapid and individualized treatment protocols depending on results, while physicians can measure progress in real-time. As this method expands into more hospitals, it is cementing its role as an instrument to facilitate better treatment and cancer care of patients as per radiopharmaceutical theranostics market forecast.
Market snapshot - 2026-2033
Global Market Size
USD 1.87 Billion
Largest Segment
Targeted therapeutic radiopharmaceuticals
Fastest Growth
Companion diagnostic radiopharmaceuticals
Growth Rate
11.1% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global Radiopharmaceutical Theranostics Market is segmented by Type, Source, Application, End User and region. Based on Type, the market is segmented into Companion Diagnostic Radiopharmaceuticals and Targeted Therapeutic Radiopharmaceuticals. Based on Source, the market is segmented into Nuclear Reactors and Cyclotrons. Based on Application, the market is segmented into Oncology, Cardiology, Neurology and Other Applications. Based on End User, the market is segmented into Hospitals, Diagnostic Imaging Centers, Research Institutes and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Targeted therapeutic radiopharmaceuticals are becoming more widely used as practitioners are being pushed to practice precision medicine, according to radiopharmaceutical theranostics market statistics. Therapeutic agents that are designed to deliver therapeutic doses of radiation directly to the site of disease while sparing surrounding healthy tissues, are an important therapeutic area for some treatment of cancers and some neurological diseases; therefore, the inclusion of radiopharmaceuticals as viable treatments is in increasing demand as the expectation of care grows in modern healthcare settings. Companion diagnostic radiopharmaceuticals play a critical role in modern medical care, but the nature of that role is fundamentally supportive rather than personal. These agents are designed to help clinicians visualize biological processes, identify disease characteristics, and determine whether a patient is likely to benefit from a specific therapy. Because their purpose is to generate objective diagnostic information, they are discussed primarily in terms of their contribution to the overall clinical workflow, therapeutic decision-making, and population-level treatment optimization—not in terms of personal or individualized patient narratives.
The use of cyclotrons as a source of radiopharmaceutical theranostics is generating traction because of the suitability of cyclotrons to make short-lived isotopes on demand as needed. Researchers and hospitals are finding cyclotron systems are more useful than previous sources, especially when considering quicker access and a growing interest in local supply of short-lived radiopharmaceuticals to lower additive costs and reliance on supply chains. While nuclear reactors are indeed less flexible and more centralized than emerging accelerator-based systems, they remain essential for producing certain long-lived radioisotopes that cannot be generated efficiently through alternative methods. Their high neutron flux, stable operating cycles, and ability to irradiate large target volumes make reactors uniquely suited for creating isotopes such as molybdenum-99, iodine-131, and various industrial or research isotopes that require sustained neutron capture processes. These capabilities ensure a reliable supply of materials vital for medical diagnostics, cancer therapy, industrial radiography, and scientific research. Despite the shift toward decentralized and more agile production technologies, reactors continue to provide foundational support to the global isotope supply chain by delivering isotopes that remain difficult or uneconomical to produce elsewhere.
To get detailed segments analysis, Request a Free Sample Report
As per radiopharmaceutical theranostics market regional outlook, North America can move more quickly because of a strong healthcare system and infrastructure, and early adoption of precision medicine in addition to significant investment in nuclear medicine research. In addition, the presence of leading pharma companies and favorable regulatory frameworks enhance uptake. With access to advanced technology, patients are benefitting from access to many new technologies that have made North America a center of innovation and deployment for radiopharmaceutical theranostics.
The United States will continue to lead this market with developed nuclear medicine facilities, a strong oncology network and clinical research. Patients in the U.S. are more aware and demanding personalized care resulting in rapid adoption. There is support and growth from Government funding, Human Health Research Funding, FDA approvals and so forth, and radiopharmaceutical theranostics is expanding into urban healthcare centres as well as regional healthcare centers nationwide.
Canada's increasing investment in development of advanced diagnostics and treatment technologies is benefiting market growth. Its synergistic relationships between the Government, research environments and hospitals enable fast-tracking of innovation. Growth in cancer cases, placement of higher demands on early detection methods and patient specific targeted therapies, will increase radiopharmaceutical theranostic uptake into urban medical centers and itself in larger provinces.
With an increasing healthcare sector in Asia Pacific, a growing cancer burden and the marginalization of nuclear medicine like radiopharmaceuticals, it is no surprise that more attention is being drawn to this region with sustained government support. Countries such as Japan, South Korea and China possess deep-rooted infrastructures and an increased appetite for precision therapies. The region can provide lower operational costs, and many patients enter clinical trials and place commercial opportunities.
Japan holds a unique national position in highly developed medical technology, an aging demographic, and relatively high cancer screening rates. The government's collaborative approach regarding nuclear medicine and a supportive reimbursement environment makes Japan an easy place for radiopharmaceutical theranostics market penetration. Japanese hospitals, Universities and research facilities are actively working to incorporate theranostics into routine cancer care, placing Japan at the forefront as a regional leader.
South Korea is quickly developing as a leader in the theranostics space through its strong investments in R&D and public-private partnerships. Combined with advanced imaging centers and highly skilled personnel, and quick adoption of new technologies, South Korea provides a great environment for innovation in theranostics. There are supportive regulatory oversight and comfort of patients accepting the novelty of targeted therapies based on radiation therapy and chemotherapy as appropriate treatment. The environment in Korea demonstrates the fastest rate of implementation of radiopharmaceutical theranostics in established hospitals.
Europe is emerging as a prominent force for growth driven by the expansion of funding for cancer research, current nuclear medicine infrastructure, and health policies that support these advances as per radiopharmaceutical theranostics market industry analysis. Cross-border collaborations and interest in academic research are provoking innovation. The focus for Europe on early diagnosis and personalized treatment is synergistic with the options that theranostics are creating, which can suggest the potential for sustained market growth in the future.
The advancement of theranostics is underpinned by strong support from the NHS, along with strong academic research and an increase in clinical trials to translate awareness into practice. The initiatives on cancer care and early diagnosis enhance the opportunity for an enabling environment for these, as well as developing the translational aspects. Cooperation between universities and biotech companies, coupled with sponsorship by regulations supporting this work, means that novel radiopharmaceuticals can be delivered into clinical practice as part of routine care, in the public NHS and in private healthcare setting.
Germany's healthcare capacity, talented labor force, and commitment to cancer research have enabled the country to lead the theranostics space. The country hosts many nuclear medicine centers and academic institutions that contribute to development and innovation. As per radiopharmaceutical theranostics market trends, the patient demand for advanced therapies and insurance coverage for targeted therapies will push hospitals to adopt radiopharmaceuticals in Germany.
Theranostics is well supported in France, with national cancer plans, health-care innovation pathways, and a strong research environment. Hospitals are embracing new diagnostic and therapeutic approaches to oncology care following their radiopharmaceutical theranostics market strategies. France offers a solid foundation for broadening the landscape of radiopharmaceutical theranostics in Europe with strong government support, public awareness campaigns, and partnerships with pharmaceutical companies.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Precision Targeting in Treatment
Rising Demand for Personalized Care
Limited Access to Radioisotopes
High Costs and Regulatory Complexity
Request Free Customization of this report to help us to meet your business objectives.
Providers of radiopharmaceutical theranostics ought to emphasize accessibility and cost-reduction to expand patient reach. New clinical applications, as well as local isotope production, may create even more avenues for both growth and impact.
There are several emerging companies that are shaping the radiopharmaceutical theranostics landscape. These companies are offering innovative routes of administration, next-gen radiotracers, and artificial intelligence-assisted imaging to improve overall precision, safety, and treatment endpoints.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the radiopharmaceutical theranostics market is gaining momentum. The demand for personalized, targeted cancer therapy is growing, and the rising cancer incidence globally, advances in nuclear imaging, etc. can lead to that success. Of course, challenges such as inconsistent isotope supply and complex regulatory obstacles can be challenging today and may continue to affect future growth. Growth is most likely to occur in the Asia-Pacific region because of the market’s developing healthcare infrastructure and the level of awareness there. Finally, continued innovation in radioisotope production and delivery mechanisms will reveal longer-term market opportunities to new sectors of a changing market.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 2.3 billion |
| Market size value in 2033 | USD 6.23 billion |
| Growth Rate | 11.7% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Radiopharmaceutical Theranostics Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Radiopharmaceutical Theranostics Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Radiopharmaceutical Theranostics Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Radiopharmaceutical Theranostics Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Radiopharmaceutical Theranostics Market size was valued at USD 1.87 Billion in 2023 and is poised to grow from USD 2.1 Billion in 2024 to USD 4.82 Billion by 2032, growing at a CAGR of 11.1% during the forecast period (2025-2032).
Providers of radiopharmaceutical theranostics ought to emphasize accessibility and cost-reduction to expand patient reach. New clinical applications, as well as local isotope production, may create even more avenues for both growth and impact. 'Telix Pharmaceuticals Limited (Australia)', 'Alpha Tau Medical Ltd. (Israel)', 'Lantheus Holdings, Inc. (United States)', 'Curium Pharma (France)', 'Advanced Accelerator Applications S.A. (France)', 'Eckert & Ziegler Strahlen- und Medizintechnik AG (Germany)', 'Jubilant Radiopharma (Canada)', 'Cardinal Health, Inc. (United States)', 'Nordion Inc. (Canada)', 'Theragnostics Ltd. (United Kingdom)', 'Sofie Biosciences, Inc. (United States)', 'Isotopia Molecular Imaging Ltd. (Israel)', 'ITM Isotope Technologies Munich SE (Germany)', 'NuView Life Sciences (United States)', 'Precirix NV (Belgium)'
Radiopharmaceutical theranostics offers clinicians advantages of diagnosing and treating disease with one targeted therapy. Using targeted therapy reduces exposure to healthy tissue, improves outcomes, and decreases recovery time for the patient, while effectively treating complex disease processes such as cancer malignancy and certain neurodegenerative disorders.
Tailored Theranostic Approaches: The advancement of personalized medicine is ushering in a new age of creativity in the realm of radiopharmaceutical theranostics with agents that are personalized to each individual's patient profile for targeted diagnosis and treatment in a single intervention. This new model of care is enhancing patient outcomes and decreasing adverse effects for patients, and is changing the patient’s experience, especially in the realm of cancer care and neurology.
Why Are Radiopharmaceutical Theranostics Advancing Faster in North America?
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
